Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says

Executive Summary

"Project BioShield" offers a model that policymakers should consider to encourage research in infectious diseases, FDA Commissioner McClellan told the Commonwealth Club in San Francisco June 9
Advertisement

Related Content

R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings
R&D “Pull” Incentives For Vaccines Need $250 Mil. Guarantee – Brookings
Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
BioShield House Compromise Could Serve As Template For Senate
BioShield House Compromise Could Serve As Template For Senate
Milken Institute Center To Study FDA Approval Process, Innovation Strategies
“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO
BIO To Propose Research Incentives For Diseases Of Developing World
Advertisement
UsernamePublicRestriction

Register

PS041978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel